156 related articles for article (PubMed ID: 37943382)
1. Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA.
Valdés-Delgado T; Aguado-Paredes A; Merino-Bohórquez V; Martín-Manzanares J; Alonso MM; Maldonado B; Castro L; Belvis M; Benítez B; Caunedo Á; Calleja MÁ; Argüelles-Arias F
Dig Dis Sci; 2024 Jan; 69(1):228-234. PubMed ID: 37943382
[TBL] [Abstract][Full Text] [Related]
2. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
[TBL] [Abstract][Full Text] [Related]
4. Analytical and clinical performance evaluation of two POC tests for therapeutic drug monitoring of infliximab.
Van den Bossche D; De Smet D; Debrabandere J; Vanpoucke H
Clin Chem Lab Med; 2019 May; 57(6):856-863. PubMed ID: 30838834
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels.
Thunberg J; Grännö O; Bergemalm D; Eriksson C; Visuri I; Eberhardson M; Halfvarson J
Scand J Gastroenterol; 2024; 59(2):150-155. PubMed ID: 37882356
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD.
Nasser Y; Labetoulle R; Harzallah I; Berger AE; Roblin X; Paul S
Dig Dis Sci; 2018 Oct; 63(10):2714-2721. PubMed ID: 29948562
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.
Bertin D; Serrero M; Grimaud JC; Desjeux A; Desplat-Jégo S
Cytokine; 2020 Feb; 126():154859. PubMed ID: 31629989
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three immunoassays for infliximab trough level monitoring in paediatric inflammatory bowel diseases.
Villemonteix J; Guérin-El Khourouj V; Hugot JP; Giardini C; Carcelain G; Martinez-Vinson C
Biologicals; 2021 Apr; 70():17-21. PubMed ID: 33676831
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits.
Laserna-Mendieta EJ; Salvador-Martín S; Arias-González L; Ruiz-Ponce M; Menchén LA; Sánchez C; López-Fernández LA; Lucendo AJ
Clin Chem Lab Med; 2019 Nov; 57(12):1906-1914. PubMed ID: 31085742
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies' Determination against ELISA.
Toja-Camba FJ; García-Quintanilla L; Rodríguez-Martinez L; Tomine J; Cajade-Pascual F; Feitosa C; Zarra-Ferro I; Barreiro-De-Acosta M; González-López J; Mondelo-García C; Fernández-Ferreiro A
Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004593
[TBL] [Abstract][Full Text] [Related]
11. SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
Teixeira FV; Sassaki LY; Saad-Hossne R; Baima JP; Magro DO; Coy CSR; Kotze PG
Arq Gastroenterol; 2018; 55(2):192-197. PubMed ID: 30043873
[TBL] [Abstract][Full Text] [Related]
12. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.
Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Dias CC; Magro F;
Aliment Pharmacol Ther; 2016 Oct; 44(7):684-92. PubMed ID: 27507790
[TBL] [Abstract][Full Text] [Related]
13. Comparison of three commercially available ELISA assays for anti-infliximab antibodies.
West TA; Sam M; Toong C
Pathology; 2021 Jun; 53(4):508-514. PubMed ID: 33272693
[TBL] [Abstract][Full Text] [Related]
14. Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA.
Lim MH; Aluzaite K; Schultz M; Casey P
J Gastroenterol Hepatol; 2020 Aug; 35(8):1302-1306. PubMed ID: 31881552
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease.
Jukic T; Drobne D; Pusavec S; Ihan A; Stubljar D; Starc A
Med Sci Monit; 2023 Feb; 29():e939084. PubMed ID: 36807319
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits.
Schmitz EM; van de Kerkhof D; Hamann D; van Dongen JL; Kuijper PH; Brunsveld L; Scharnhorst V; Broeren MA
Clin Chem Lab Med; 2016 Jul; 54(7):1211-9. PubMed ID: 26587745
[TBL] [Abstract][Full Text] [Related]
17. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling.
Freeman K; Connock M; Auguste P; Taylor-Phillips S; Mistry H; Shyangdan D; Court R; Arasaradnam R; Sutcliffe P; Clarke A
Health Technol Assess; 2016 Nov; 20(83):1-288. PubMed ID: 27845027
[TBL] [Abstract][Full Text] [Related]
19. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
20. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases.
Van Stappen T; Billiet T; Vande Casteele N; Compernolle G; Brouwers E; Vermeire S; Gils A
Inflamm Bowel Dis; 2015 Sep; 21(9):2172-7. PubMed ID: 26284296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
